Yale researchers receive grant for typhoid fever vaccine
Approximately 270,000 people worldwide die from typhoid fever every year, with the biggest health burden for nations that lack water sanitation and quality. The research approach is established on statistical and mathematical models that are designed to approximate how cost-effective a typhoid fever based on Vi-conjugate vaccines would be for developing countries.
This new vaccine applies the antigen for typhoid Vi, the foundation for the traditional typhoid vaccine. The antigen joins another antigen to create a stronger immune response. This could cause stronger, longer-lasting protection against typhoid.
Currently, there are several typhoid vaccine candidates in the developmental stages of research.
“Our preliminary modeling results suggest that Vi-conjugate vaccines are likely to be cost-effective in medium and high incidence settings, but it will be difficult to eliminate typhoid through vaccination alone,” Virginia Pitzer, assistant professor at the Yale School of Public Health, said. “We also plan to look at how other interventions, such as those targeted toward improving water quality and sanitation, can also help to reduce the burden of typhoid in endemic countries.”